Ginkgo Bioworks/$DNA
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Ginkgo Bioworks
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
Ticker
$DNA
Sector
Primary listing
NYSE
Industry
Chemicals
Headquarters
Employees
834
ISIN
US37611X2099
Website
Ginkgo Bioworks Metrics
BasicAdvanced
$745M
-
-$8.92
1.29
-
Price and volume
Market cap
$745M
Beta
1.29
52-week high
$16.85
52-week low
$5.00
Average daily volume
1.4M
Financial strength
Current ratio
4.881
Quick ratio
4.704
Long term debt to equity
67.121
Total debt to equity
67.121
Interest coverage (TTM)
-4,156.53%
Profitability
EBITDA (TTM)
-325.197
Gross margin (TTM)
80.04%
Net profit margin (TTM)
-198.84%
Operating margin (TTM)
-164.57%
Effective tax rate (TTM)
0.09%
Revenue per employee (TTM)
$280,000
Management effectiveness
Return on assets (TTM)
-16.99%
Return on equity (TTM)
-57.76%
Valuation
Price to revenue (TTM)
2.836
Price to book
1.07
Price to tangible book (TTM)
1.2
Price to free cash flow (TTM)
-1.95
Free cash flow yield (TTM)
-51.29%
Free cash flow per share (TTM)
-652.41%
Growth
Revenue change (TTM)
13.76%
Earnings per share change (TTM)
-48.63%
3-year revenue growth (CAGR)
-18.47%
3-year earnings per share growth (CAGR)
-48.93%
Bulls say / Bears say
Ginkgo Bioworks' strategic partnership with Google Cloud aims to develop large language models for genomics and synthetic biology, potentially accelerating innovation and discovery in these fields. (benzinga.com)
The collaboration with Pfizer to advance novel RNA molecules includes potential milestone payments and royalties up to $331 million, providing a significant financial boost and validating Ginkgo's platform. (investing.com)
In Q1 2025, Ginkgo reported a 27% increase in total revenue to $48 million, driven by a $7 million rise in cell engineering revenue, indicating strong growth in its core business segment. (finviz.com)
Ginkgo's Q4 2024 net loss was $107.5 million, exceeding analyst estimates of $80.1 million, raising concerns about its path to profitability. (tradingview.com)
The company forecasted 2025 revenue between $160 million and $180 million, below analyst expectations of $189 million, suggesting potential challenges in meeting growth targets. (tradingview.com)
Ginkgo's stock has declined 82.4% over the past 12 months, reflecting investor skepticism and potential challenges in the biotech sector. (tradingview.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ginkgo Bioworks stock?
Ginkgo Bioworks (DNA) has a market cap of $745M as of July 04, 2025.
What is the P/E ratio for Ginkgo Bioworks stock?
The price to earnings (P/E) ratio for Ginkgo Bioworks (DNA) stock is 0 as of July 04, 2025.
Does Ginkgo Bioworks stock pay dividends?
No, Ginkgo Bioworks (DNA) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next Ginkgo Bioworks dividend payment date?
Ginkgo Bioworks (DNA) stock does not pay dividends to its shareholders.
What is the beta indicator for Ginkgo Bioworks?
Ginkgo Bioworks (DNA) has a beta rating of 1.29. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.